Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAN 2025 | Multiple sclerosis highlights from EAN 2025: new diagnostic criteria and broad rim lesions

Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, shares her highlights from the 11th Congress of the European Academy of Neurology (EAN 2025). She highlights the new McDonald diagnostic criteria, which are expected to be published later this year, and the identification of a new type of lesion associated with disease progression. This interview took place at the 11th Congress of the European Academy of Neurology (EAN 2025) in Helsinki, Finland

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

So there was a lot of sessions around multiple sclerosis this year and I think the highlight first was the presentation of the new criteria, diagnostic criteria of McDonald, that they are almost published. They will be published now in summer and this new criteria can allow us to have a better diagnosis, less misdiagnosis and to have the diagnosis in patients with a very early disease. So patients that have perhaps only an optic neuritis with some lesions than before they were not MS, they were only clinically isolated syndrome, it means the step before MS and now we can have these patients, they will have the diagnosis of MS and that is important because when you have the diagnosis of MS, we can start the treatment of this patient...

So there was a lot of sessions around multiple sclerosis this year and I think the highlight first was the presentation of the new criteria, diagnostic criteria of McDonald, that they are almost published. They will be published now in summer and this new criteria can allow us to have a better diagnosis, less misdiagnosis and to have the diagnosis in patients with a very early disease. So patients that have perhaps only an optic neuritis with some lesions than before they were not MS, they were only clinically isolated syndrome, it means the step before MS and now we can have these patients, they will have the diagnosis of MS and that is important because when you have the diagnosis of MS, we can start the treatment of this patient. So this new criteria allow us to have a better diagnosis and to have less misdiagnosis. And the second point that was interesting in this Congress was we are looking for different kinds of lesions in the brain, lesions that can help us to know and to know more about the progression. And they have presented the new kind of lesion that is the broad rim lesions, that is the BRL lesions, and this lesion it seems that they are very related, very associated with the progression of the disease.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Disclosures

C Oreja-Guevara received honoraria for speaking, consulting and serving on advisory boards from Alexion, Amgen, Biogen Idec, BMS, Horizon, Janssen, Merck, Novartis, Roche, Sanofi-Genzyme, Sandoz, Viatris, Neuraxpharm and Teva.